EpiCast Report Growth Hormone Deficiency Epidemiology Forecast to 2026
ReportsWeb.com published “Growth Hormone Deficiency Epidemiology Market” from its
database. The report covers the market landscape and its growth prospects over the coming
years. The report also includes a discussion of the key vendors operating in this market.
GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary
gland. GHD is more commonly seen in children, although it can develop during adulthood. GHD
can be present from birth (congenital) , or it can be secondary due to brain trauma (acquired) .
Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone
development and bone lengthening later on. Patients who acquire GHD later in life present
with more generalized symptoms, such as increased abdominal fat, decreased levels of energy,
and decrease in muscle mass. In young children, certain kinds of cancer treatments, such as
cranial radiation, can increase the chances of developing GHD. Other clinical procedures, such
as brain surgery, can increase a patient's chances of developing GHD. GHD may be hereditary,
or it may be due to fetal malformation or genetic mutations. Acquired GHD can be caused by
trauma to the head or brain and more commonly by a pituitary adenoma.
For more information about this report: http://www.reportsweb.com/epicast-report-growth-
hormone-deficiency-epidemiology-forecast-to-2026
In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase
from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26%
in the 7MM. Publisher epidemiologists forecast an increase in the diagnosed prevalent cases of
GHD in all markets except Germany and Japan. In 2016, the US made up about 48% of all
diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%,
and Japan made up nearly 13% of all cases of GHD in the 7MM.
This 10-year epidemiological forecast of GHD is supported by data obtained from international
GHD disease monitoring databases, country-specific government sources, as well as peer
reviewed studies using market-relevant disease definitions across the 7MM. This forecast
provides detailed segmentations within GHD for each market by the patient's age, sex, and
etiological classification (congenital and idiopathic in children, and idiopathic and acquired in
adults) , thus creating a comprehensive view of the epidemiology of GHD in the 7MM. Publisher
epidemiologists maintained consistent forecast methodology across all seven markets, thus
allowing for an accurate and meaningful comparison of included parameters among them.